The evidence.
The care.
The access.
Evidence · Published 26 October 2026
In the 715-participant MIRA2 trial, hysterectomy within two years occurred in 4% of women receiving combined treatment and 10% receiving endometrial ablation alone.
Read the article ↗Photo: Adobe Stock
The latest news
Independent women’s-health reporting on what changed, why it matters and what to watch next.
In ERBB2-low advanced breast cancer, median progression-free survival was 16.4 months with the antibody-drug conjugate versus 6.8 months with physician-selected chemotherapy—but severe toxicity was common.
The Ontario cohort found higher delivery-hospitalization morbidity with excessive gestational weight gain across every prepregnancy BMI category; the observational findings are not personal weight targets.
By 2025, researchers estimated 90,460 telehealth provisions under shield laws to residents of 13 total-ban states, while more than 64,000 residents still travelled for care.
In interviews with 15 Australian women, participants described missed symptoms, fragmented care and a median of seven healthcare contacts while seeking support.
Health & science
Research, medicine and technology—reported with the limits, source and unanswered questions intact.
In the 715-participant MIRA2 trial, hysterectomy within two years occurred in 4% of women receiving combined treatment and 10% receiving endometrial ablation alone.
Among 593 patients receiving routine counselling, adding the US Patient Agreement Form did not produce a clinically meaningful improvement in knowledge.
Both groups improved while receiving first-line supportive care, but five laser sessions added no measurable benefit over sham treatment at 12 months.
Policy & access
Health policy, regulation, care delivery and the decisions that determine who can access care.
The estradiol–levonorgestrel patch is therapeutically equivalent to Climara Pro; approval does not establish its retail price, insurance coverage or pharmacy availability.
The new service combines acute appointments with follow-up when recurring symptoms need further assessment.
The virtual-care company plans to expand clinical technology, partnerships and research across hormonal, metabolic and reproductive health.
From the archive
Historical news publications use the source or event date and are clearly marked as archive reporting.
Explore 20 archive news publications ↗
The non-invasive endometriosis test can be marketed in the EU, while US use remains research-only and independent clinical validation is still limited.
FDA clearance of an investigational application allows a planned Phase 1 study to proceed; it is not approval of the treatment, and no human efficacy data have been reported.
The generic version of Imvexxy adds another potential access route for painful sex associated with menopausal vulvar and vaginal atrophy.
Forty recommendations address prevention, diagnosis, staged treatment, psychosocial support and the affordability of fertility care.